Antonio Piga

List of Publications by Year
in descending order

63 papers	7,072 citations	125106 35 h-index	139680 61 g-index
63 all docs	63 docs citations	63 times ranked	4141 citing authors

#	Article	IF	Citations
1	The Influence of Cardiovascular Risk Factors and Hypogonadism on Cardiac Outcomes in an Aging Population of Beta-Thalassemia Patients. Journal of Cardiovascular Development and Disease, 2022, 9, 3.	0.8	3
2	Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring. Scientific Reports, 2021, 11, 12581.	1.6	6
3	Changing patterns of thalassaemia in Italy: a WebThal perspective. Blood Transfusion, 2021, 19, 261-268.	0.3	2
4	Myocardial longitudinal strain as the first herald of cardiac impairment in very early iron overload state: an echocardiography and biosusceptometry study on beta-thalassemia patients. American Journal of Cardiovascular Disease, 2021, 11, 555-563.	0.5	0
5	Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited. Internal and Emergency Medicine, 2019, 14, 365-370.	1.0	13
6	Challenges of blood transfusions in Î²-thalassemia. Blood Reviews, 2019, 37, 100588.	2.8	123
7	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. Pharmacogenomics Journal, 2019, 19, 417-427.	0.9	6
8	Dual-Energy X-ray Absorptiometry Predictors of Vertebral Deformities in Beta-Thalassemia Major. Journal of Clinical Densitometry, 2018, 21, 507-516.	0.5	5
9	Clinical relevance of deferasirox trough levels in Î²â€thalassemia patients. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 213-216.	0.9	3
10	Atrial fibrillation in Î²-thalassemia Major Patients: Diagnosis, Management and Therapeutic Options. Hemoglobin, 2018, 42, 189-193.	0.4	15
11	Deferasirox pharmacokinetic evaluation in Î²-thalassaemia paediatric patientsâ€. Journal of Pharmacy and Pharmacology, 2017, 69, 525-528.	1.2	5
12	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics, 2017, 18, 539-554.	0.6	14
13	Liver stiffness assessed by transient elastography in patients with Î² thalassaemia major. Annals of Hepatology, 2016, 15, 410-417.	0.6	13
14	A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. Blood, 2016, 128, 1555-1561.	0.6	47
15	Deferasirox pharmacokinetic and toxicity correlation in Î²-thalassaemia major treatmentâ€. Journal of Pharmacy and Pharmacology, 2016, 68, 1417-1421.	1.2	9
16	Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics, 2016, 17, 571-582.	0.6	15
17	Sustained improvements in myocardial T2* over 2 years in severely ironâ€overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology, 2015, 90, 91-96.	2.0	43
18	Prevalence and distribution of iron overload in patients with transfusionâ€dependent anemias differs across geographic regions: results from the <scp>CORDELIA</scp> study. European Journal of Haematology, 2015, 95, 244-253.	1.1	61

#	Article	IF	Citations
19	Children of a lesser god or miracles? An emotional and behavioural profile of children born to mothers on dialysis in Italy: a multicentre nationwide study 2000â€“12. Nephrology Dialysis Transplantation, 2015, 30, 1193-1202.	0.4	8
20	Deferasirox effect on renal haemodynamic parameters in patients with transfusionâ€dependent Î² thalassaemia. British Journal of Haematology, 2015, 168, 882-890.	1.2	27
21	Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. British Journal of Haematology, 2014, 167, 121-126.	1.2	69
22	A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in Î²-thalassemia major (CORDELIA). Blood, 2014, 123, 1447-1454.	0.6	97
23	Amlodipine Reduces Cardiac Iron Overload in Patients with Thalassemia Major: A Pilot Trial. American Journal of Medicine, 2013, 126, 834-837.	0.6	51
24	Assessment and management of iron overload in Î²â€thalassaemia major patients during the 21st century: a realâ€life experience from the <scp>I</scp>talian <scp>W</scp>ebthal project. British Journal of Haematology, 2013, 161, 872-883.	1.2	31
25	Cardiovascular Function and Treatment in Î²-Thalassemia Major. Circulation, 2013, 128, 281-308.	1.6	301
26	A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood, 2012, 119, 3263-3268.	0.6	48
27	A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 893-894, 127-133.	1.2	29
28	Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 34.	1.6	32
29	Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial. Movement Disorders, 2011, 26, 1755-1759.	2.2	125
30	Changing patterns of splenectomy in transfusionâ€dependent thalassemia patients. American Journal of Hematology, 2011, 86, 808-810.	2.0	32
31	Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood, 2011, 118, 884-893.	0.6	181
32	Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study. European Journal of Echocardiography, 2011, 12, 242-246.	2.3	16
33	Deferiprone. Annals of the New York Academy of Sciences, 2010, 1202, 75-78.	1.8	40
34	Pregnancy and Â-thalassemia: an Italian multicenter experience. Haematologica, 2010, 95, 376-381.	1.7	103
35	High nontransferrin bound iron levels and heart disease in thalassemia major. American Journal of Hematology, 2009, 84, 29-33.	2.0	128
36	Severe iron overload in Blackfanâ€Diamond anemia: A caseâ€control study. American Journal of Hematology, 2009, 84, 729-732.	2.0	48

#	Article	IF	Citations
37	Efficacy and safety of deferasirox doses of >30â€ƒmg/kg per d in patients with transfusionâ€dependent anaemia and iron overload. British Journal of Haematology, 2009, 147, 752-759.	1.2	101
38	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176.	1.1	210
39	Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen. Journal of Clinical Pharmacology, 2008, 48, 428-435.	1.0	36
40	Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica, 2008, 93, 741-752.	1.7	182
41	Current Status in Iron Chelation in Hemoglobinopathies. Current Molecular Medicine, 2008, 8, 663-674.	0.6	31
42	Agreement of liver iron quantification measurements with low Tc-SQUID biosusceptometers in Oakland, Torino and Hamburg. International Congress Series, 2007, 1300, 279-282.	0.2	0
43	Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood, 2006, 107, 3733-3737.	0.6	338
44	Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 2006, 107, 3738-3744.	0.6	424
45	A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006, 107, 3455-3462.	0.6	636
46	Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica, 2006, 91, 873-80.	1.7	210
47	Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica, 2006, 91, 1343-51.	1.7	109
48	Monitoring Long-Term Efficacy of Iron Chelation Treatment with Biomagnetic Liver Susceptometry. Annals of the New York Academy of Sciences, 2005, 1054, 350-357.	1.8	57
49	Purging iron from the heart. British Journal of Haematology, 2004, 125, 545-551.	1.2	34
50	Hepatocellular carcinoma in the thalassaemia syndromes. British Journal of Haematology, 2004, 124, 114-117.	1.2	147
51	A Phase II Study with ICL670 (ExjadeÂ®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.. Blood, 2004, 104, 3193-3193.	0.6	17
52	Once-Daily Treatment with the Oral Iron Chelator ICL670 (ExjadeÂ®): Results of a Phase II Study in Pediatric Patients with Î²-Thalassemia Major.. Blood, 2004, 104, 3614-3614.	0.6	11
53	Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 2004, 89, 1187-93.	1.7	772
54	Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with Î²-thalassaemia major: application of SQUID biomagnetic liver susceptometry. British Journal of Haematology, 2003, 121, 938-948.	1.2	100

#	Article	IF	Citations
55	Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood, 2003, 102, 1583-1587.	0.6	284
56	Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood, 2002, 100, 1566-1569.	0.6	162
57	The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. British Journal of Haematology, 2002, 118, 330-336.	1.2	192
58	Deferiprone therapy in homozygous human Î²-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. Translational Research, 1999, 133, 64-69.	2.4	29
59	A Multi-Center Safety Trial of the Oral Iron Chelator Deferiprone. Annals of the New York Academy of Sciences, 1998, 850, 223-226.	1.8	42
60	Survival and Disease Complications in Thalassemia Major. Annals of the New York Academy of Sciences, 1998, 850, 227-231.	1.8	312
61	Late Effects of Bone Marrow Transplantation for Thalassemiaa. Annals of the New York Academy of Sciences, 1998, 850, 294-299.	1.8	19
62	Results of Long-Term Iron-Chelating Therapy. Acta Haematologica, 1996, 95, 26-36.	0.7	348
63	SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR. Lancet, The, 1989, 334, 27-30.	6.3	520